TICKERNERD
Menu
CRSPCRSPHealthcare · Biotechnology

CRSP Stock Forecast: CRISPR Therapeutics AG Price Predictions for 2026-2027

Last close, 2 Oct 2026
$55
−0.02% on the day

The 22 Wall Street analysts covering CRISPR Therapeutics AG hold a median 12-month price target of $80 — +44.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 3 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.4B
Ticker Nerd rank
37 / 100
Median analyst target
$80
Analysts covering
22
Revenue$10.0M
Operating income−$117.3M
Net income−$91.2M
Free cash flow−$86.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.2%
1M
−2.6%
YTD
+5.7%
1Y
−23.9%
From 52W high
−27.8%
From 52W low
+25.0%
$44
$77
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CRSP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CRISPR Therapeutics AG on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
72
Value
60
Growth
54
Accruals
50
Volatility
47
Momentum
47
Quality
46
Size
22
Issuance
12

Revisions (72): Analysts have, on balance, been raising their forecasts.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CRSP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CRSP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200$250$300Jan 26Apr 26Jul 26Oct 26CRSPHigh $291Median $80Low $44

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
13 Buy9 Hold0 Sell
Low $44Median $80High $291

The green dot is the last close — the median target sits +44.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Aug 2026CitizensReiteratesMarket Outperform$80
31 Aug 2026NeedhamReiteratesBuy$82
25 Aug 2026CitizensReiteratesMarket Outperform$80
4 Aug 2026CitigroupMaintainsBuy$82 → $88
4 Aug 2026CitigroupMaintainsBuy—
8 July 2026HC Wainwright & Co.ReiteratesBuy$80
8 July 2026HC Wainwright & Co.ReiteratesBuy—
6 July 2026CitizensReiteratesMarket Outperform$80
6 July 2026CitizensReiteratesMarket Outperform—
13 May 2026BernsteinMaintainsMarket Perform—
6 May 2026CitigroupMaintainsBuy—
17 Mar 2026Piper SandlerReiteratesOverweight—
17 Feb 2026Chardan CapitalMaintainsBuy—
13 Feb 2026Evercore ISI GroupMaintainsOutperform—
13 Feb 2026NeedhamMaintainsBuy—
13 Feb 2026TD CowenMaintainsHold—
30 Jan 2026CitizensMaintainsMarket Outperform—
23 Dec 2025CitizensReiteratesMarket Outperform—
23 Dec 2025NeedhamReiteratesBuy—
26 Nov 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CRSP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CRSP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, CRISPR Therapeutics AG returned −23.9% against +16.2% for the S&P 500, dividends included.

CRSP vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26CRSPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CRSP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
12
Analysts cutting
3
Fundamentals

CRISPR Therapeutics AG (CRSP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.6×

Cheaper than 92% of US stocks

Price / sales
400.2×

Cheaper than 2% of US stocks

Price / book
3.1×

Cheaper than 31% of US stocks

EV / EBITDA
−7.4×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
1041.4%

Higher than 99% of US stocks

Earnings growth (YoY)
—
Gross margin
−302.7%

Higher than 1% of US stocks

Operating margin
−1127.6%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−26.1%

Higher than 29% of US stocks

Return on assets
−14.2%

Higher than 23% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CRISPR Therapeutics AG (CRSP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CRISPR Therapeutics AG has a market value of $5.4B and an enterprise value of $3.8B.

  • Revenue in the twelve months to 30 June 2026: $11.0M. The latest quarter grew 1041.4% year on year.

  • Net income over the same four quarters: −$451.1M, a −4101.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.76.

  • Free cash flow in the twelve months to 30 June 2026: −$373.8M.

  • Shares outstanding: 96.7M.

  • Trailing P/E: −8.6×; forward P/E: −15.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • CRISPR Therapeutics AG employs 393 people — $28K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

CRSP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CRSPCRISPR Therapeutics AG$5.4B
37
COGTCogent Biosciences, Inc.$5.3B
34
TVTXTravere Therapeutics, Inc.$5.4B
86
PTCTPTC Therapeutics, Inc.$5.3B
64
MIRMMirum Pharmaceuticals, Inc.$5.4B
66
ORKAOruka Therapeutics, Inc.$5.6B
40
ERASErasca, Inc.$5.0B
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CRISPR Therapeutics AG — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CRSP news & analysis

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

GlobeNewsWire · 2 Oct 2026positive

CRISPR Therapeutics announced that a poster presentation of Phase 1 clinical data for its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

Why it matters — This news highlights an upcoming presentation of early clinical data for zugo-cel in autoimmune disease, which marks a potential expansion of CRISPR Therapeutics' pipeline beyond oncology into a new therapeutic area.

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Zacks Investment Research · 29 Sept 2026neutral

CRISPR Therapeutics (CRSP) has attracted increased attention from investors on Zacks.com recently. The article suggests it is worth exploring what lies ahead for the stock.

Why it matters — CRSP watchers would want to know that the stock is drawing heightened investor interest and to consider what may be ahead for the company.

CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?

The Motley Fool · 29 Sept 2026positive

CRISPR Therapeutics has two key data readouts expected by the end of 2026. In each case, the company will need to show its candidate is more effective than both alternatives in development and treatments already on the market.

Why it matters — A CRSP watcher would care because these upcoming clinical data readouts represent pivotal milestones that could determine the competitiveness and prospects of the company's pipeline candidates.

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why

Zacks Investment Research · 25 Sept 2026negative

CRISPR Therapeutics AG (CRSP) closed at $54.23 on the latest trading day, down 2.64% from its previous close, a decline that occurred while the broader market gained.

Why it matters — A CRSP watcher would note that the stock underperformed the market on the day, falling despite broader market gains.

Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing

Seeking Alpha · 24 Sept 2026neutral

CRISPR Therapeutics remains a long-term Buy, anchored by Casgevy's commercial success, with Q2 sales growing 78% sequentially. Anthropic's AI-driven gene editing discovery introduces potential competitive and funding risks, though clinical impact appears distant.

Why it matters — A CRSP watcher would care because Anthropic's AI-driven gene editing discovery could introduce competitive and funding risks, even as Casgevy's strong sequential sales growth supports the company's core commercial position.

FAQ

Frequently asked questions about CRSP stock

What is the CRSP stock price forecast for 2026-2027?

The 22 Wall Street analysts covering CRISPR Therapeutics AG have a median 12-month price target of $80, with estimates ranging from $44 to $291. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CRSP stock a buy right now?

Of the 22 analysts covering CRISPR Therapeutics AG, 13 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CRISPR Therapeutics AG 37 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CRSP?

As at 3 Oct 2026, CRISPR Therapeutics AG ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (72 of 100).

Will CRSP stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +44.3% from the last close, and Ticker Nerd's factor model ranks CRISPR Therapeutics AG 37 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CRSP stock forecast for 2030?

No analyst covering CRISPR Therapeutics AG publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CRSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $44 to $291 over the next 12 months.

How has CRSP stock performed over the past year?

CRISPR Therapeutics AG returned -23.9% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing and the development of CRISPR/Cas9-based medicines for serious human diseases. Its research and therapeutic portfolio spans areas such as hemoglobinopathies, oncology, regenerative medicine, autoimmune disorders, and type 1 diabetes.

What is the latest news on CRSP?

The most recent item we track (GlobeNewsWire, 2 Oct 2026): "CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026". CRISPR Therapeutics announced that a poster presentation of Phase 1 clinical data for its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune disease, will be presented at the American College of Rheumatology (ACR) Convergence 2026.

Company

About CRISPR Therapeutics AG.

CRISPR Therapeutics AG is a Swiss biotechnology company focused on gene editing and the development of CRISPR/Cas9-based medicines for serious human diseases. Its research and therapeutic portfolio spans areas such as hemoglobinopathies, oncology, regenerative medicine, autoimmune disorders, and type 1 diabetes. The company’s work centers on using precise genome editing to create targeted cell and gene therapies, with a particular emphasis on advancing treatments derived from its proprietary CRISPR platform. CRISPR Therapeutics AG also collaborates with partners in the life sciences sector to develop and commercialize selected programs, strengthening its role in the broader healthcare innovation landscape. Headquartered in Zug, Switzerland, the company is a notable participant in the biotechnology market, where it contributes to the growing field of gene-based medicine.

CEO Dr. Samarth Kulkarni Ph.D. · 393 employees · Switzerland · https://www.crisprtx.com